Salt of Syk inhibitor and crystalline form thereof

US12187710B2 · kind B2 · utility

Assignee

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · CN

Inventors

• Wenyuan Qian · Newbury Park, US
• Hongjian Wang · 盐官镇, CN
• Ming Zhang · Beijing, CN
• Fei Liu · Nanjing, CN
• Lei Xing · Palo Alto, US
• Zhongyuan Hu · 流花街道, CN
• Yahui Guo · Wuxi, CN
• Yanlong Liu · Shandong, CN
• Huihui Zhang · Longbeilingcun, CN

Key dates

• Filing date: Dec 13, 2019
• Grant date: Jan 7, 2025
• Expiry date: May 12, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided is a salt of an Syk inhibitor and a crystalline form thereof, and more specifically, provided are 5-fluoro-1-methyl-3-((5-(4-(oxetan-3-yl)piperazine-1)-yl)pyridin-2-yl)amino)-6-(1H-pyrazol-3-yl)quinoline-2(1H)-ketamine hydrochloride, a crystalline form thereof, a preparation method therefor, a pharmaceutical composition thereof and a use thereof. The hydrochloride of the compound represented by formula I and the crystalline form thereof have good salt-forming properties, high stability and low hygroscopicity, have advantages in terms of physical properties, safety and metabolic stability, and have value in prepared medicines.